{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:39:16Z","timestamp":1765546756792,"version":"3.37.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The translocase of outer mitochondrial membrane 40 (<jats:italic>TOMM40<\/jats:italic>) <jats:italic>\u2018523\u2019<\/jats:italic> polymorphism has previously been associated with age of Alzheimer\u2019s disease onset and cognitive functioning in non-pathological ageing, but has not been explored as a candidate risk marker for cognitive decline in Parkinson\u2019s disease (PD). Therefore, this longitudinal study investigated the role of the <jats:italic>\u2018523\u2019<\/jats:italic> variant in cognitive decline in a patient cohort from the Parkinson\u2019s Progression Markers Initiative. As such, a group of 368 people with PD were assessed annually for cognitive performance using multiple neuropsychological protocols, and were genotyped for the <jats:italic>TOMM40 \u2018523\u2019<\/jats:italic> variant using whole-genome sequencing data. Covariate-adjusted generalised linear mixed models were utilised to examine the relationship between <jats:italic>TOMM40 \u2018523\u2019<\/jats:italic> allele lengths and cognitive scores, while taking into account the <jats:italic>APOE<\/jats:italic> \u03b5 genotype. Cognitive scores declined over the 5-year study period and were lower in males than in females. When accounting for <jats:italic>APOE<\/jats:italic> \u03b54, the <jats:italic>TOMM40 \u2018523\u2019<\/jats:italic> variant was not robustly associated with overall cognitive performance. However, in <jats:italic>APOE<\/jats:italic> \u03b53\/\u03b53 carriers, who accounted for ~60% of the whole cohort, carriage of shorter <jats:italic>\u2018523\u2019<\/jats:italic> alleles was associated with more severe cognitive decline in both sexes, while carriage of the longer alleles in females were associated with better preservation of global cognition and a number of cognitive sub-domains, and with a delay in progression to dementia. The findings indicate that when taken in conjunction with the <jats:italic>APOE<\/jats:italic> genotype, <jats:italic>TOMM40 \u2018523\u2019<\/jats:italic> allele length is a significant independent determinant and marker for the trajectory of cognitive decline and risk of dementia in PD.<\/jats:p>","DOI":"10.1038\/s41531-021-00200-y","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T10:04:51Z","timestamp":1625652291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["TOMM40 \u2018523\u2019 poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-6827","authenticated-orcid":false,"given":"Megan C.","family":"Bakeberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastazja M.","family":"Gorecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2231-9800","authenticated-orcid":false,"given":"Abigail L.","family":"Pfaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-3490","authenticated-orcid":false,"given":"Madison E.","family":"Hoes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6087-6643","authenticated-orcid":false,"given":"Sulev","family":"K\u00f5ks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Anthony","family":"Akkari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank L.","family":"Mastaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-9794","authenticated-orcid":false,"given":"Ryan S.","family":"Anderton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"200_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27, 349\u2013356 (2012).","journal-title":"Mov. Disord."},{"key":"200_CR2","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.parkreldis.2015.08.024","volume":"21","author":"G Santangelo","year":"2015","unstructured":"Santangelo, G. et al. Mild cognitive impairment in newly diagnosed Parkinson\u2019s disease: a longitudinal prospective study. Parkinsonism Relat. Disord. 21, 1219\u20131226 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"200_CR3","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/npjparkd.2016.18","volume":"2","author":"R Biundo","year":"2016","unstructured":"Biundo, R., Weis, L. & Antonini, A. Cognitive decline in Parkinson\u2019s disease: the complex picture. NPJ Park. Dis. 2, 16018 (2016).","journal-title":"NPJ Park. Dis."},{"key":"200_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep33929","volume":"6","author":"BJ Lawrence","year":"2016","unstructured":"Lawrence, B. J., Gasson, N. & Loftus, A. M. Prevalence and subtypes of mild cognitive impairment in Parkinson\u2019s disease. Sci. Rep. 6, 33929 (2016).","journal-title":"Sci. Rep."},{"key":"200_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40478-019-0717-3","volume":"7","author":"AKL Liu","year":"2019","unstructured":"Liu, A. K. L. et al. Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinson\u2019s disease with cognitive decline. Acta Neuropathol. Commun. 7, 61 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"200_CR6","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.2147\/NDT.S88968","volume":"11","author":"W Liu","year":"2015","unstructured":"Liu, W. et al. The impact of nonmotor symptoms on quality of life in patients with Parkinson\u2019s disease in Taiwan. Neuropsychiatr. Dis. Treat. 11, 2865\u20132873 (2015).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"200_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fpsyt.2016.00089","volume":"7","author":"LM Collins","year":"2016","unstructured":"Collins, L. M. & Williams-Gray, C. H. The genetic basis of cognitive impairment and dementia in Parkinson\u2019s disease. Front. psychiatry 7, 89 (2016).","journal-title":"Front. psychiatry"},{"key":"200_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","volume":"13","author":"D Aarsland","year":"2017","unstructured":"Aarsland, D. et al. Cognitive decline in Parkinson disease. Nat. Rev. Neurol. 13, 217\u2013231 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"200_CR9","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e318253d54b","volume":"78","author":"RN Alcalay","year":"2012","unstructured":"Alcalay, R. N. et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 78, 1434\u20131440 (2012).","journal-title":"Neurology"},{"key":"200_CR10","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/mds.27845","volume":"34","author":"H Iwaki","year":"2019","unstructured":"Iwaki, H. et al. Genomewide association study of Parkinson\u2019s disease clinical biomarkers in 12 longitudinal patients\u2019 cohorts. Mov. Disord. 34, 1839\u20131850 (2019).","journal-title":"Mov. Disord."},{"key":"200_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/mds.28342","volume":"36","author":"MMX Tan","year":"2020","unstructured":"Tan, M. M. X. et al. Genome-wide association studies of cognitive and motor progression in Parkinson\u2019s disease. Mov. Disord. 36, 424\u2013433 (2020).","journal-title":"Mov. Disord."},{"key":"200_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1517\/17425255.2016.1133586","volume":"12","author":"AD Roses","year":"2016","unstructured":"Roses, A. D. et al. Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing. Expert Opin. Drug Metab. Toxicol. 12, 135\u2013147 (2016).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"200_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cell.2017.12.017","volume":"172","author":"DE Dickel","year":"2018","unstructured":"Dickel, D. E. et al. Ultraconserved enhancers are required for normal development. Cell 172, 491\u2013499.e15 (2018).","journal-title":"Cell"},{"key":"200_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fncel.2019.00058","volume":"13","author":"M Elkouris","year":"2019","unstructured":"Elkouris, M. et al. Long non-coding RNAs associated with neurodegeneration-linked genes are reduced in Parkinson\u2019s disease patients. Front. Cell. Neurosci. 13, 58 (2019).","journal-title":"Front. Cell. Neurosci."},{"key":"200_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fnins.2020.00047","volume":"14","author":"F Theunissen","year":"2020","unstructured":"Theunissen, F. et al. Structural variants may be a source of missing heritability in sALS. Front. Neurosci. 14, 47 (2020).","journal-title":"Front. Neurosci."},{"key":"200_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jalz.2012.10.009","volume":"9","author":"AD Roses","year":"2013","unstructured":"Roses, A. D. et al. TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. Alzheimer\u2019s Dement. 9, 132\u2013136 (2013).","journal-title":"Alzheimer\u2019s Dement."},{"key":"200_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jalz.2010.01.011","volume":"6","author":"MW Lutz","year":"2010","unstructured":"Lutz, M. W., Crenshaw, D. G., Saunders, A. M. & Roses, A. D. Genetic variation at a single locus and age of onset for Alzheimer\u2019s disease. Alzheimers Dement. 6, 125\u2013131 (2010).","journal-title":"Alzheimers Dement."},{"key":"200_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/tpj.2009.69","volume":"10","author":"AD Roses","year":"2010","unstructured":"Roses, A. D. et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer\u2019s disease. Pharmacogenomics J. 10, 375\u2013384 (2010).","journal-title":"Pharmacogenomics J."},{"key":"200_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1212\/WNL.0000000000003614","volume":"88","author":"L Yu","year":"2017","unstructured":"Yu, L. et al. TOMM40\u2019523 variant and cognitive decline in older persons with APOE \u03b53\/3 genotype. Neurology 88, 661\u2013668 (2017).","journal-title":"Neurology"},{"key":"200_CR20","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.jalz.2017.05.002","volume":"13","author":"L Yu","year":"2017","unstructured":"Yu, L. et al. Neuropathologic features of TOMM40 \u2019523 variant on late-life cognitive decline. Alzheimers Dement. 13, 1380\u20131388 (2017).","journal-title":"Alzheimers Dement."},{"key":"200_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jalz.2010.11.012","volume":"7","author":"SC Johnson","year":"2011","unstructured":"Johnson, S. C. et al. The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE \u03b53\/\u03b53 genotype. Alzheimer\u2019s Dement. 7, 456\u2013465 (2011).","journal-title":"Alzheimer\u2019s Dement."},{"key":"200_CR22","doi-asserted-by":"publisher","first-page":"217.e1","DOI":"10.1016\/j.neurobiolaging.2015.11.017","volume":"39","author":"A Payton","year":"2016","unstructured":"Payton, A. et al. A TOMM40 poly-T variant modulates gene expression and is associated with vocabulary ability and decline in nonpathologic aging. Neurobiol. Aging 39, 217.e1\u2013217.e7 (2016).","journal-title":"Neurobiol. Aging"},{"key":"200_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-017-0267-0","volume":"10","author":"K Nho","year":"2017","unstructured":"Nho, K. et al. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer\u2019s disease. BMC Med. Genomics 10, 29 (2017).","journal-title":"BMC Med. Genomics"},{"key":"200_CR24","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1016\/j.bbadis.2017.07.031","volume":"1863","author":"K Zeitlow","year":"2017","unstructured":"Zeitlow, K. et al. The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer\u2019s disease. Biochim. Biophys. Acta 1863, 2973\u20132986 (2017).","journal-title":"Biochim. Biophys. Acta"},{"key":"200_CR25","doi-asserted-by":"publisher","first-page":"e62277","DOI":"10.1371\/journal.pone.0062277","volume":"8","author":"A Bender","year":"2013","unstructured":"Bender, A. et al. TOM40 mediates mitochondrial dysfunction induced by \u03b1-synuclein accumulation in Parkinson\u2019s disease. PLoS ONE 8, e62277 (2013).","journal-title":"PLoS ONE"},{"key":"200_CR26","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1074\/jbc.M710012200","volume":"283","author":"L Devi","year":"2008","unstructured":"Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G. & Anandatheerthavarada, H. K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283, 9089\u20139100 (2008).","journal-title":"J. Biol. Chem."},{"key":"200_CR27","first-page":"12","volume":"1","author":"WK Gottschalk","year":"2014","unstructured":"Gottschalk, W. K. et al. The broad impact of TOM40 on neurodegenerative diseases in aging. Park. Dis. Alzheimer\u2019s Dis. 1, 12 (2014).","journal-title":"Park. Dis. Alzheimer\u2019s Dis."},{"key":"200_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/DDDT.S130514","volume":"11","author":"G Ganguly","year":"2017","unstructured":"Ganguly, G., Chakrabarti, S., Chatterjee, U. & Saso, L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer\u2019s disease and Parkinson\u2019s disease. Drug Des. Devel. Ther. 11, 797\u2013810 (2017).","journal-title":"Drug Des. Devel. Ther."},{"key":"200_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbadis.2009.09.013","volume":"1802","author":"B Su","year":"2010","unstructured":"Su, B. et al. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim. Biophys. Acta 1802, 135\u2013142 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"200_CR30","doi-asserted-by":"crossref","unstructured":"Han, Z. et al. Parkinson\u2019s disease and Alzheimer\u2019s disease: a Mendelian randomization study. BMC Med. Genet. 19, 215 (2018).","DOI":"10.1186\/s12881-018-0721-7"},{"key":"200_CR31","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1002\/mds.27434","volume":"33","author":"J Laffita\u2010Mesa","year":"2018","unstructured":"Laffita\u2010Mesa, J., Brodin, L. & Svenningsson, P. Nucleotide repeats as genetic risk factors in a Swedish Parkinson\u2019s disease cohort. Mov. Disord. 33, S14\u2013S117 (2018).","journal-title":"Mov. Disord."},{"key":"200_CR32","doi-asserted-by":"publisher","first-page":"2078.e1","DOI":"10.1016\/j.neurobiolaging.2013.02.018","volume":"34","author":"B Peplonska","year":"2013","unstructured":"Peplonska, B. et al. TOMM40 and APOE common genetic variants are not Parkinson\u2019s disease risk factors. Neurobiol. Aging 34, 2078.e1\u20132078.e2 (2013).","journal-title":"Neurobiol. Aging"},{"key":"200_CR33","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1038\/s41598-021-85510-0","volume":"11","author":"M Bakeberg","year":"2021","unstructured":"Bakeberg, M. et al. The TOMM40 \u2018523' polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson&rq disease. Sci. Rep 11, 6363 (2021).","journal-title":"Sci. Rep"},{"key":"200_CR34","first-page":"99","volume":"6","author":"D Lindqvist","year":"2016","unstructured":"Lindqvist, D., Prokopenko, I., Londos, E., Middleton, L. & Hansson, O. Associations between TOMM40 Poly-T repeat variants and dementia in cases with parkinsonism. J. Park. Dis. 6, 99\u2013108 (2016).","journal-title":"J. Park. Dis."},{"key":"200_CR35","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1002\/mds.23388","volume":"25","author":"IN Miller","year":"2010","unstructured":"Miller, I. N. & Cronin-Golomb, A. Gender differences in Parkinson\u2019s disease: clinical characteristics and cognition. Mov. Disord. 25, 2695\u20132703 (2010).","journal-title":"Mov. Disord."},{"key":"200_CR36","doi-asserted-by":"publisher","first-page":"e0133002","DOI":"10.1371\/journal.pone.0133002","volume":"10","author":"EF Augustine","year":"2015","unstructured":"Augustine, E. F. et al. Sex differences in clinical features of early, treated Parkinson\u2019s disease. PLoS ONE 10, e0133002 (2015).","journal-title":"PLoS ONE"},{"key":"200_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3389\/fneur.2018.00482","volume":"9","author":"S-J Lin","year":"2018","unstructured":"Lin, S.-J., Baumeister, T. R., Garg, S. & McKeown, M. J. Cognitive profiles and hub vulnerability in Parkinson\u2019s disease. Front. Neurol. 9, 482 (2018).","journal-title":"Front. Neurol."},{"key":"200_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41531-020-0109-1","volume":"6","author":"TH Reekes","year":"2020","unstructured":"Reekes, T. H. et al. Sex specific cognitive differences in Parkinson disease. npj Park. Dis. 6, 7 (2020).","journal-title":"npj Park. Dis."},{"key":"200_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/mds.28312","volume":"36","author":"H Iwaki","year":"2020","unstructured":"Iwaki, H. et al. Differences in the presentation and progression of Parkinson\u2019s disease by sex. Mov. Disord. 36, 106\u2013117 (2020).","journal-title":"Mov. Disord."},{"key":"200_CR40","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00415-020-10367-8","volume":"268","author":"MC Bakeberg","year":"2021","unstructured":"Bakeberg, M. C. et al. Differential effects of sex on longitudinal patterns of cognitive decline in Parkinson\u2019s disease. J. Neurol. 268, 1903\u20131912 (2021).","journal-title":"J. Neurol."},{"key":"200_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4103\/aian.AIAN_262_17","volume":"21","author":"S Chaudhary","year":"2018","unstructured":"Chaudhary, S. et al. Comparison of cognitive profile in young- and late-onset Parkinson\u2019s disease patients. Ann. Indian Acad. Neurol. 21, 130\u2013132 (2018).","journal-title":"Ann. Indian Acad. Neurol."},{"key":"200_CR42","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/brain\/awh067","volume":"127","author":"T Foltynie","year":"2004","unstructured":"Foltynie, T., Brayne, C. E. G., Robbins, T. W. & Barker, R. A. The cognitive ability of an incident cohort of Parkinson\u2019s patients in the UK. The CamPaIGN study. Brain 127, 550\u2013560 (2004).","journal-title":"Brain"},{"key":"200_CR43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1468-1331.2008.02514.x","volume":"16","author":"MM Wickremaratchi","year":"2009","unstructured":"Wickremaratchi, M. M., Ben-Shlomo, Y. & Morris, H. R. The effect of onset age on the clinical features of Parkinson\u2019s disease. Eur. J. Neurol. 16, 450\u2013456 (2009).","journal-title":"Eur. J. Neurol."},{"key":"200_CR44","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1212\/WNL.56.6.730","volume":"56","author":"D Aarsland","year":"2001","unstructured":"Aarsland, D. et al. Risk of dementia in Parkinson\u2019s disease: a community-based, prospective study. Neurology 56, 730\u2013736 (2001).","journal-title":"Neurology"},{"key":"200_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3109\/00207454.2015.1010646","volume":"126","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Cognitive profile of Parkinson\u2019s disease patients: a comparative study between early-onset and late-onset Parkinson\u2019s disease. Int. J. Neurosci. 126, 227\u2013234 (2016).","journal-title":"Int. J. Neurosci."},{"key":"200_CR46","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3233\/JAD-160597","volume":"55","author":"Y Kim","year":"2016","unstructured":"Kim, Y. et al. Cognitive and neuroanatomical correlates in early versus late onset Parkinson\u2019s disease dementia. J. Alzheimer\u2019s Dis. 55, 485\u2013495 (2016).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"200_CR47","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.4161\/auto.25884","volume":"9","author":"G Bertolin","year":"2013","unstructured":"Bertolin, G. et al. The TOMM machinery is a molecular switch in PINK1 and PARK2\/PARKIN-dependent mitochondrial clearance. Autophagy 9, 1801\u20131817 (2013).","journal-title":"Autophagy"},{"key":"200_CR48","doi-asserted-by":"crossref","unstructured":"Bussies, P. L. et al. Use of local genetic ancestry to assess TOMM40-523\u2032 and risk for Alzheimer disease. Neurol. Genet. 6, e404 (2020).","DOI":"10.1212\/NXG.0000000000000404"},{"key":"200_CR49","doi-asserted-by":"publisher","first-page":"e30994","DOI":"10.1371\/journal.pone.0030994","volume":"7","author":"C Linnertz","year":"2012","unstructured":"Linnertz, C. et al. Characterization of the poly-T variant in the TOMM40 gene in diverse populations. PLoS ONE 7, e30994 (2012).","journal-title":"PLoS ONE"},{"key":"200_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"K Marek","year":"2011","unstructured":"Marek, K. et al. The Parkinson progression marker initiative (PPMI). Prog. Neurobiol. 95, 629\u2013635 (2011).","journal-title":"Prog. Neurobiol."},{"key":"200_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22, 41\u201347 (2007).","journal-title":"Mov. Disord."},{"key":"200_CR52","first-page":"45","volume":"8","author":"AV Lebedev","year":"2014","unstructured":"Lebedev, A. V. et al. Large-scale resting state network correlates of cognitive impairment in Parkinson\u2019s disease and related dopaminergic deficits. Front. Syst. Neurosci. 8, 45 (2014).","journal-title":"Front. Syst. Neurosci."},{"key":"200_CR53","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/mds.26170","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D. et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease. Mov. Disord. 30, 919\u2013927 (2015).","journal-title":"Mov. Disord."},{"key":"200_CR54","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0000000000000483","volume":"82","author":"JB Pereira","year":"2014","unstructured":"Pereira, J. B. et al. Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology 82, 2017\u20132025 (2014).","journal-title":"Neurology"},{"key":"200_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","volume":"12","author":"RHB Benedict","year":"1998","unstructured":"Benedict, R. H. B., Schretlen, D., Groninger, L. & Brandt, J. Hopkins verbal learning test \u2013 revised: normative data and analysis of inter-form and test-retest reliability. Clin. Neuropsychol. 12, 43\u201355 (1998).","journal-title":"Clin. Neuropsychol."},{"key":"200_CR56","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/archneur.1978.00500300038006","volume":"35","author":"AL Benton","year":"1978","unstructured":"Benton, A. L., Varney, N. R. & Hamsher, K. D. Visuospatial judgment: a clinical test. Arch. Neurol. 35, 364\u2013367 (1978).","journal-title":"Arch. Neurol."},{"key":"200_CR57","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/arclin\/acu055","volume":"29","author":"KM Kiely","year":"2014","unstructured":"Kiely, K. M., Butterworth, P., Watson, N. & Wooden, M. The symbol digit modalities test: normative data from a large nationally representative sample of australians. Arch. Clin. Neuropsychol. 29, 767\u2013775 (2014).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"200_CR58","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/mds.27335","volume":"33","author":"KA Wyman-Chick","year":"2018","unstructured":"Wyman-Chick, K. A. et al. Selection of normative group affects rates of mild cognitive impairment in Parkinson\u2019s disease. Mov. Disord. 33, 839\u2013843 (2018).","journal-title":"Mov. Disord."},{"key":"200_CR59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.acn.2005.07.003","volume":"21","author":"LK Sheridan","year":"2006","unstructured":"Sheridan, L. K. et al. Normative Symbol Digit Modalities Test performance in a community-based sample. Arch. Clin. Neuropsychol. 21, 23\u201328 (2006).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"200_CR60","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois, B. et al. Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22, 2314\u20132324 (2007).","journal-title":"Mov. Disord."},{"key":"200_CR61","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre, M. et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov. Disord. 22, 1689\u20131707 (2007).","journal-title":"Mov. Disord."},{"key":"200_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"200_CR63","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.nbd.2012.02.002","volume":"46","author":"M Federoff","year":"2012","unstructured":"Federoff, M., Jimenez-Rolando, B., Nalls, M. A. & Singleton, A. B. A large study reveals no association between APOE and Parkinson\u2019s disease. Neurobiol. Dis. 46, 389\u2013392 (2012).","journal-title":"Neurobiol. Dis."},{"key":"200_CR64","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/mds.20968","volume":"21","author":"R Inzelberg","year":"2006","unstructured":"Inzelberg, R. et al. Association between amantadine and the onset of dementia in Parkinson\u2019s disease. Mov. Disord. 21, 1375\u20131379 (2006).","journal-title":"Mov. Disord."},{"key":"200_CR65","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/mds.26615","volume":"31","author":"D Papadimitriou","year":"2016","unstructured":"Papadimitriou, D. et al. Motor and nonmotor features of carriers of the p.A53T alpha\u2010synuclein mutation: a longitudinal study. Mov. Disord. 31, 1226\u20131230 (2016).","journal-title":"Mov. Disord."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00200-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00200-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00200-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T21:53:00Z","timestamp":1670017980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00200-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1038\/s41531-021-00200-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"type":"electronic","value":"2373-8057"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}